Supply of the products Erythromycin by Link Medical Products

Overview

The Therapeutic Goods Act 1989 was enacted to establish a national system for regulating therapeutic goods, including medicines, medical devices, blood and tissues, in Australia. The Act was introduced to address the need for a unified regulatory framework to ensure that therapeutic goods available in the market are safe, of acceptable quality, and perform as claimed. The Act is administered by the Therapeutic Goods Administration, which operates under the Department of Health. The policy objective of the Act is to protect public health by regulating the supply and advertising of therapeutic goods. On December 17, 2013, the delegate of the Secretary of the Department of Health granted consent for the supply of certain erythromycin products by Link Medical Products, subject to specific conditions that address non-compliance with labelling requirements as per TGO 69, while ensuring ongoing communication through updated contact details.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation and control of therapeutic goods in Australia, ensuring that these goods meet the required standards of quality, safety, and efficacy. This Act applies to persons and entities involved in the supply, manufacture, and advertising of therapeutic goods, including medicines, medical devices, and blood and blood components. The Act has a national reach, operating under the Commonwealth jurisdiction to regulate the therapeutic goods market across Australia. While the Act covers a broad range of therapeutic goods, there are specific exclusions and exemptions provided under various sections and orders. For instance, certain goods such as tobacco products are excluded from the definition of therapeutic goods under the Act. Additionally, the application of the Act may be extended or restricted through subordinate instruments such as therapeutic goods orders, which detail specific requirements and standards for different categories of therapeutic goods. In this particular case, the consent granted by the delegate of the Secretary pertains to the supply of specific batches of erythromycin products that do not fully conform to the label requirements set out in Therapeutic Goods Order 69, subject to conditions including the redirection of written correspondence to the current address of the supplier.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) is pivotal in regulating therapeutic goods in Australia, and section 14 and 14A specifically address the supply of therapeutic goods that do not fully comply with the standards outlined in Therapeutic Goods Orders (TGO). In this instance, the Act permits the supply of erythromycin (as ethylsuccinate) (EES) 200 mg/5 mL granules for oral liquid and erythromycin (as ethylsuccinate) (EES) 400 mg/5 mL granules for oral liquid under specific conditions, despite non-compliance with TGO 69, which pertains to the labelling requirements of the products (s14). The consent granted by the delegate of the Secretary is explicitly tied to particular batch numbers, ensuring that the products in question can be identified and monitored (s14A). Entities governed by the Act must adhere to stringent requirements to ensure the safety and quality of therapeutic goods. Under this consent, the Company, Link Medical Products, must ensure that the bottle labels for the specified products accurately reflect the current address of the sponsor, while the carton labels may temporarily retain the old address until corrected. Additionally, the Company is obligated to have arrangements in place to redirect all written correspondence to the current address. These measures are designed to maintain transparency and traceability in the supply chain, which are crucial for regulatory oversight (s15(1)). Failure to comply with the conditions set forth in the Act can result in serious consequences. Breaches of the Act or the Therapeutic Goods Regulations could lead to both civil and criminal penalties. Under the Act, non-compliance may result in fines, with the maximum penalty varying depending on the severity of the breach. For example, section 24 of the Act stipulates that individuals and companies can face substantial fines for breaches related to the supply of non-compliant therapeutic goods. Moreover, persistent or egregious violations may lead to more severe criminal penalties, including imprisonment, as outlined in section 31 of the Act. In summary, the Therapeutic Goods Act 1989 imposes rigorous standards and requirements on entities involved in the supply of therapeutic goods in Australia. The specific consent granted under sections 14 and 14A mandates compliance with certain conditions, including the accurate labelling of products and the redirection of correspondence to current addresses. Non-compliance with these provisions can result in significant civil and criminal penalties, reinforcing the importance of adhering to the regulatory framework established by the Act.